Dimerix Limited (ASX:DXB)

Australia flag Australia · Delayed Price · Currency is AUD
0.4620
+0.0120 (2.67%)
Sep 3, 2025, 12:33 PM AEST
2.67%
Market Cap270.08M
Revenue (ttm)5.59M
Net Income (ttm)-13.25M
Shares Out600.18M
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,019,085
Average Volume1,234,843
Open0.4500
Previous Close0.4500
Day's Range0.4500 - 0.4700
52-Week Range0.3000 - 0.7850
Beta0.53
RSI38.39
Earnings DateAug 28, 2025

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Nina Webster
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol DXB
Full Company Profile

Financial Performance

In 2025, Dimerix's revenue was 5.59 million, an increase of 1271.12% compared to the previous year's 407,466. Losses were -13.25 million, -22.39% less than in 2024.

Financial Statements

News

Biotech Dimerix lands $940m licensing deal for kidney drug sales

The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.

4 months ago - The Australian Financial Review